Curavac

Executive Summary

CuraVac is a clinical-stage biotechnology company based in Leuven, Belgium, focused on developing Targeted Active Therapies and Active Targeted Immunotherapies for autoimmune diseases. Founded in 2002, the company leverages a novel complementary peptide technology to induce long-term immunity against autoimmune targets, aiming to provide durable treatments rather than symptomatic relief. Currently in Phase 2 development, CuraVac's approach represents a potential paradigm shift in autoimmune disease management, offering the possibility of disease modification or even cure. With no disclosed funding or valuation, the company operates privately, but its technology platform has attracted interest in the biopharma community. The company's progress through clinical trials positions it for potential value-inflection points as it advances toward regulatory milestones.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Data Readout for Lead Autoimmune Indication40% success
• H1 2027Strategic Partnership or Licensing Deal50% success
• Q2 2027Regulatory Guidance Meeting with EMA/FDA70% success